Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by Viking2233on Jul 27, 2024 7:31pm
223 Views
Post# 36151412

Petite Pete on a Roll

Petite Pete on a RollNow that you have replayed everything Arch has accomplished, which is impressive to say the least.

Pete, I have received a few private messages asking if you work for Arch. I have no idea if you do or not but you have clearly demonstrated what Arch has accomplished over the years.

Can you share with everyone any of the following:

1. How many patients have been dosed to date in Turkish trial?

2. Has a signal been observed in  the Turkish sites?

3. When will Canadian sites actually get final approvals and start dosing?

4. When will Pontiac Trial commence dosing?

5. Why is there a lack of interest or buyers in Arch with everything they have accomplished as you have outlined?

6. Why is there 0% institutional ownership in Arch with everything they have accomplished and where they are at?

7. Why is Arch share price 30% lower from 1 year ago?

8. Why is Arch market cap at $100M, yet dimilar dtaged peers are valued at $750M to $2B

9. Will Arch receive anymore government grants$

The above points are what modt are waiting for.
<< Previous
Bullboard Posts
Next >>